Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
1.470
-0.018 (-1.21%)
At close: Jun 27, 2025, 4:00 PM
1.440
-0.030 (-2.04%)
After-hours: Jun 27, 2025, 4:00 PM EDT
Cellectis Revenue
Cellectis had revenue of $12.03M in the quarter ending March 31, 2025, with 85.10% growth. This brings the company's revenue in the last twelve months to $54.75M, up 351.26% year-over-year. In the year 2024, Cellectis had annual revenue of $49.22M with 435.37% growth.
Revenue (ttm)
$54.75M
Revenue Growth
+351.26%
P/S Ratio
1.89
Revenue / Employee
$246,608
Employees
222
Market Cap
103.25M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
CLLS News
- 1 day ago - Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025 - GlobeNewsWire
- 5 weeks ago - Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025 - GlobeNewsWire
- 6 weeks ago - Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy - Seeking Alpha
- 6 weeks ago - Cellectis Reports Financial Results for the First Quarter 2025 - GlobeNewsWire
- 7 weeks ago - Cellectis to Report First Quarter Financial Results on May 12, 2025 - GlobeNewsWire
- 2 months ago - Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting - GlobeNewsWire
- 3 months ago - Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update - GlobeNewsWire